acetylcysteine has been researched along with Parkinsonian Disorders in 28 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 9 (32.14) | 29.6817 |
2010's | 18 (64.29) | 24.3611 |
2020's | 1 (3.57) | 2.80 |
Authors | Studies |
---|---|
Du, Y; Guan, Y; Hao, Y; Le, W; Li, Z; Song, Y; Wang, F; Yang, X | 1 |
Dexter, DT; Harrison, IF; Powell, NM | 1 |
Cuenca, L; Estrada, C; Fernández-Villalba, E; Gil-Martínez, AL; Herrero, MT; Sánchez, C | 1 |
Assous, M; Gubellini, P; Had-Aissouni, L; Kachidian, P; Kerkerian-Le-Goff, L; Melon, C; Nafia, I; Salin, P | 1 |
Bui, LC; Dairou, J; Lamouri, A; Leger, T; Mihoub, M; Richarme, G | 1 |
Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Nowak, P | 1 |
Hassanzadeh, K; Izadpanah, E; Khosrobakhsh, F; Moloudi, MR; Rahimmi, A | 1 |
Elson, JL; Pienaar, IS; Yates, A | 1 |
Anis, HK; Dexter, DT; Harrison, IF | 1 |
Angelatou, F; Antonopoulos, I; Botsakis, K; Georgiou, CD; Grintzalis, K; Margarity, M; Matsokis, NA; Panagopoulos, NT; Theodoritsi, S | 1 |
Czarnecka, A; Konieczny, J; Lenda, T | 1 |
Antkiewicz-Michaluk, L; Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T | 1 |
Dairou, J; Richarme, G | 1 |
Bentea, E; Churchill, MJ; Deneyer, L; Hood, RL; Massie, A; Meshul, CK; Moore, C; Verbruggen, L | 1 |
Hashimoto, T; Ibuki, T; Iwanaga, T; Kishibuchi, R; Kitagawa, H; Mizuguchi, H; Momota, H; Nishihara, S; Onaka, Y; Sado, M; Wada, D; Watanabe, TK; Yamasaki, Y | 1 |
Johansson, SM; Modo, MM; Vernon, AC | 1 |
Amit, T; Bar-Am, O; Prosolovich, K; Weinreb, O; Youdim, MB | 1 |
Ito, H; Matsui, H; Takahashi, R; Takeda, S; Taniguchi, Y | 1 |
Ahmad, I; Kumar, A; Kumar, V; Pandey, HP; Patel, DK; Shukla, S; Singh, BK; Singh, C; Srivastava, G | 1 |
Hintermann, S; Jankovic, J; Le, W; Li, X; Tuo, H; Xie, WJ; Zhang, Z | 1 |
Branton, RL; Brundin, P; Clarke, DJ; Karlsson, J; Love, RM | 1 |
Bisceglio, G; Farrer, MJ; Hulihan, M; Kachergus, J; Lincoln, S; Lockhart, PJ; Mash, DC; Wilkes, K | 1 |
Conn, KJ; Eisenhauer, PB; Fine, RE; Gao, W; Lan, MS; McKee, A; Ullman, MD; Wells, JM | 1 |
Le, W; Pan, T; Qu, S; Wang, X; Xie, W; Zhang, X | 1 |
Halliwell, B; Hyun, DH; Jenner, P; Lee, M | 1 |
Agarwal, V; Diwakar, L; Iyengar, S; Karunakaran, S; Ramakrishnan, S; Ravindranath, V; Saeed, U | 1 |
Hattori, N; Imai, Y; Inoue, H; Mizuno, Y; Soda, M; Takahashi, R | 1 |
Kudo, M; Shimoke, K | 1 |
28 other study(ies) available for acetylcysteine and Parkinsonian Disorders
Article | Year |
---|---|
HDAC6-mediated Hsp90 deacetylation reduces aggregation and toxicity of the protein alpha-synuclein by regulating chaperone-mediated autophagy.
Topics: Acetylcysteine; alpha-Synuclein; Animals; Chaperone-Mediated Autophagy; Histone Deacetylase 6; HSP90 Heat-Shock Proteins; Humans; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Protein Aggregates | 2021 |
The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease.
Topics: Acetylation; Acetylcysteine; Animals; Cell Death; Disease Models, Animal; Dopaminergic Neurons; Histone Deacetylase Inhibitors; Male; Nerve Degeneration; Niacinamide; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2019 |
Effect of NAC treatment and physical activity on neuroinflammation in subchronic Parkinsonism; is physical activity essential?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcysteine; Analysis of Variance; Animals; Calcium-Binding Proteins; Disease Models, Animal; Encephalitis; Glial Fibrillary Acidic Protein; Imaging, Three-Dimensional; Male; Mice; Mice, Inbred C57BL; Microfilament Proteins; Microscopy, Confocal; Neuroprostanes; Parkinsonian Disorders; Physical Conditioning, Animal; S100 Calcium Binding Protein beta Subunit; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2018 |
Progressive Parkinsonism by acute dysfunction of excitatory amino acid transporters in the rat substantia nigra.
Topics: Acetylcysteine; Action Potentials; Animals; Dicarboxylic Acids; Disease Models, Animal; Exploratory Behavior; Forelimb; Free Radical Scavengers; Functional Laterality; Glutamate Decarboxylase; Glutamate Plasma Membrane Transport Proteins; In Vitro Techniques; Male; Motor Activity; Neuroglia; Neurotransmitter Uptake Inhibitors; Parkinsonian Disorders; Pyrrolidines; Rats; Rats, Wistar; Substantia Nigra; Thiobarbituric Acid Reactive Substances; Tyrosine 3-Monooxygenase | 2014 |
Parkinsonism-associated protein DJ-1/Park7 is a major protein deglycase that repairs methylglyoxal- and glyoxal-glycated cysteine, arginine, and lysine residues.
Topics: Acetylcysteine; Albumins; Apoptosis; Arginine; Aspartate Aminotransferases; Catalysis; Cell Survival; Cysteine; Escherichia coli; Fructose-Bisphosphate Aldolase; Glucose; Glycolates; Glyoxal; Humans; Intracellular Signaling Peptides and Proteins; Lactates; Lysine; Mass Spectrometry; Oncogene Proteins; Oxidative Stress; Parkinsonian Disorders; Protein Deglycase DJ-1; Pyruvaldehyde | 2015 |
Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Cell Count; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; GABA-A Receptor Agonists; Homovanillic Acid; Locomotion; Male; Muscimol; Neurons; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats, Wistar; Receptors, GABA-A; Substantia Nigra | 2015 |
N-acetylcysteine prevents rotenone-induced Parkinson's disease in rat: An investigation into the interaction of parkin and Drp1 proteins.
Topics: Acetylcysteine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Drug Interactions; Dynamins; Male; Oxidative Stress; Parkinsonian Disorders; Protein Binding; Random Allocation; Rats; Rats, Wistar; Rotarod Performance Test; Rotenone; Substantia Nigra; Ubiquitin-Protein Ligases | 2015 |
Pedunculopontine cell loss and protein aggregation direct microglia activation in parkinsonian rats.
Topics: Acetylcysteine; alpha-Synuclein; Animals; Cell Count; Choline O-Acetyltransferase; Cholinergic Neurons; Disease Models, Animal; Dopaminergic Neurons; Male; Microglia; Neurons; Parkinson Disease; Parkinsonian Disorders; Pars Compacta; Pedunculopontine Tegmental Nucleus; Protein Aggregation, Pathological; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2016 |
Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate.
Topics: Acetylcysteine; Animals; Dopaminergic Neurons; Male; Neuroprotective Agents; Parkinsonian Disorders; Proteasome Inhibitors; Rats, Sprague-Dawley; Substantia Nigra; Valproic Acid; Ventral Tegmental Area | 2016 |
17β-Estradiol/N-acetylcysteine interaction enhances the neuroprotective effect on dopaminergic neurons in the weaver model of dopamine deficiency.
Topics: Acetylcysteine; Animals; Dopaminergic Neurons; Drug Synergism; Estradiol; Female; Immunohistochemistry; Male; Mice; Mice, Neurologic Mutants; Nerve Degeneration; Neuroprotective Agents; Parkinsonian Disorders | 2016 |
Early increase in dopamine release in the ipsilateral striatum after unilateral intranigral administration of lactacystin produces spontaneous contralateral rotations in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Amphetamine; Animals; Benzazepines; Central Nervous System Agents; Corpus Striatum; Dopamine; Dopamine Antagonists; Functional Laterality; Glutamic Acid; Haloperidol; Homovanillic Acid; Male; Movement; Parkinsonian Disorders; Rats, Wistar; Receptors, Dopamine; Rotation; Substantia Nigra | 2016 |
The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA.
Topics: Acetylcysteine; Amphetamine; Animals; Apomorphine; Benzazepines; Central Nervous System Stimulants; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Functional Laterality; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Raclopride; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation | 2017 |
Parkinsonism-associated protein DJ-1 is a bona fide deglycase.
Topics: Acetylcysteine; Artifacts; Culture Media; Cysteine; Escherichia coli; Glucose; Glycation End Products, Advanced; Glycosylation; Glyoxal; Humans; Intracellular Signaling Peptides and Proteins; Mutation; Oncogene Proteins; Parkinsonian Disorders; Protein Deglycase DJ-1; Pyruvaldehyde | 2017 |
Plastic changes at corticostriatal synapses predict improved motor function in a partial lesion model of Parkinson's disease.
Topics: Acetylcysteine; Animals; Behavior, Animal; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Male; Mice, Inbred C57BL; Motor Activity; Neural Pathways; Neuronal Plasticity; Parkinson Disease; Parkinsonian Disorders; Pars Compacta; Post-Synaptic Density; Rotarod Performance Test; Synapses | 2017 |
Protective effect against Parkinson's disease-related insults through the activation of XBP1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcysteine; Animals; Cell Death; Cell Line; Cell Survival; Cysteine Proteinase Inhibitors; DNA-Binding Proteins; Dopamine; Endoplasmic Reticulum; Endoribonucleases; Humans; Leupeptins; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Parkinsonian Disorders; Protein Serine-Threonine Kinases; Regulatory Factor X Transcription Factors; RNA, Messenger; Signal Transduction; Stress, Physiological; Transcription Factors; X-Box Binding Protein 1 | 2009 |
Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.
Topics: Acetylcysteine; alpha-Synuclein; Animals; Apomorphine; Corpus Striatum; Cysteine Proteinase Inhibitors; Disease Models, Animal; Dopamine; Dopamine Agonists; Iron; Magnetic Resonance Imaging; Male; Mesencephalon; Motor Activity; Neurons; Parkinsonian Disorders; Random Allocation; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2010 |
Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease?
Topics: Acetylcysteine; Animals; Catalase; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Humans; Hydrogen Peroxide; Indans; Male; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; PC12 Cells; Rats; Rats, Sprague-Dawley | 2011 |
Ammonium chloride and tunicamycin are novel toxins for dopaminergic neurons and induce Parkinson's disease-like phenotypes in medaka fish.
Topics: Acetylcysteine; Ammonium Chloride; Animals; Disease Models, Animal; Dopamine; Nerve Tissue Proteins; Neurons; Neurotoxins; Oryzias; Parkinsonian Disorders; Phenotype; Substantia Nigra; Tunicamycin | 2010 |
Involvement of NADPH oxidase and glutathione in zinc-induced dopaminergic neurodegeneration in rats: similarity with paraquat neurotoxicity.
Topics: Acetophenones; Acetylcysteine; Animals; Apoptosis; Caspases; CD11b Antigen; Corpus Striatum; Cytochromes c; Dopamine; Dopaminergic Neurons; Enzyme Inhibitors; Glutathione; Male; Membrane Glycoproteins; Mitochondria; Motor Activity; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Paraquat; Parkinsonian Disorders; Phosphoproteins; Rats; Rats, Wistar; Serotonin; Substantia Nigra; Tyrosine 3-Monooxygenase | 2012 |
Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease.
Topics: Acetylcysteine; Animals; Cysteine Proteinase Inhibitors; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Mice; Mice, Inbred C57BL; Microglia; Motor Activity; Neostriatum; Nuclear Receptor Subfamily 4, Group A, Member 2; Parkinsonian Disorders; Proteasome Endopeptidase Complex; Real-Time Polymerase Chain Reaction; RNA, Messenger; Substantia Nigra; Transcriptional Activation; Vesicular Monoamine Transport Proteins | 2012 |
Effects of antioxidant pretreatment on the survival of embryonic dopaminergic neurons in vitro and following grafting in an animal model of Parkinson's disease.
Topics: Acetylcysteine; Animals; Antioxidants; Cells, Cultured; Chromans; Disease Models, Animal; Dopamine; Drug Combinations; Female; Fetus; Glutathione; Graft Survival; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stem Cell Transplantation; Stem Cells; Substantia Nigra | 2002 |
DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function.
Topics: Acetylcysteine; Adolescent; Adult; Age of Onset; Amino Acid Sequence; Animals; Cell Line; DNA Mutational Analysis; Female; Genes, Recessive; Humans; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Molecular Sequence Data; Mutation; Oncogene Proteins; Parkinsonian Disorders; Protein Deglycase DJ-1; RNA, Messenger | 2004 |
Identification of the protein disulfide isomerase family member PDIp in experimental Parkinson's disease and Lewy body pathology.
Topics: 1-Methyl-4-phenylpyridinium; Acetylcysteine; Aged; Aged, 80 and over; Analysis of Variance; Animals; Blotting, Northern; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Dopamine; Female; Gene Expression Regulation; Humans; Immunohistochemistry; Lewy Bodies; Male; Middle Aged; Neuroblastoma; Nuclear Proteins; Parkinsonian Disorders; Postmortem Changes; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tretinoin | 2004 |
Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration.
Topics: Acetylcysteine; Animals; Deferoxamine; Iron Chelating Agents; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neuroprotective Agents; Parkinsonian Disorders; Proteasome Inhibitors; Substantia Nigra; Treatment Outcome; Ubiquitin | 2005 |
Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults.
Topics: 1-Methyl-4-phenylpyridinium; Acetylcysteine; Aldehydes; Apoptosis; Cell Death; Cell Line, Tumor; Drug Resistance; Enzyme Inhibitors; Genetic Predisposition to Disease; Glutamic Acid; Guanine; Humans; Hydrogen Peroxide; Mutation; Nerve Degeneration; Neurons; Neurotoxins; Oxidative Stress; Parkinsonian Disorders; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Substantia Nigra; Tyrosine; Ubiquitin-Protein Ligases | 2005 |
Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcysteine; Alkynes; Animals; Antioxidants; Antiparkinson Agents; Biotransformation; Carrier Proteins; Cell Nucleus; Co-Repressor Proteins; Cystathionine gamma-Lyase; Cytosol; Dopamine; Drug Evaluation, Preclinical; Electron Transport Complex I; Enzyme Activation; Glutathione; Glycine; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 4; MAP Kinase Kinase Kinase 5; MAP Kinase Signaling System; Mesencephalon; Mice; Mice, Inbred C57BL; Molecular Chaperones; MPTP Poisoning; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Nuclear Proteins; Oncogene Proteins; Parkinsonian Disorders; Peroxiredoxins; Phosphorylation; Protein Deglycase DJ-1; Protein Processing, Post-Translational; Protein Transport; Substantia Nigra; Thioctic Acid | 2007 |
An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin.
Topics: Acetylcysteine; Brain; Cell Death; Cells, Cultured; Cysteine Proteinase Inhibitors; Endoplasmic Reticulum; Humans; Ligases; Microscopy, Fluorescence; Parkinsonian Disorders; Precipitin Tests; Protein Binding; Protein Folding; Receptors, Cell Surface; Recombinant Fusion Proteins; Two-Hybrid System Techniques; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligases; Ubiquitins | 2001 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine has a transient proliferative effect on PC12h cells and nerve growth factor additively promotes this effect: possible involvement of distinct mechanisms of activation of MAP kinase family proteins.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcysteine; Animals; Apoptosis; Brain; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Free Radical Scavengers; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Nerve Growth Factor; Neurons; p38 Mitogen-Activated Protein Kinases; Parkinsonian Disorders; PC12 Cells; Protein Serine-Threonine Kinases; Rats; Reactive Oxygen Species | 2002 |